Merck & Co. Inc. (NYSE:MRK) ranks among the 14 safe stocks to buy now for a starter stock portfolio. Merck & Co. Inc. (NYSE:MRK) ranks among the 14 safe stocks to buy now for a starter stock portfolio ...

Merck & Co., Inc. (NYSE:MRK) has been on a strong recovery run, gaining 23% over the past year and 8% year-to-date, though the stock has pulled back some, now well below its 52-week high of $125.14.

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...

Thousands of jobs could be on the horizon for American workers as drug manufacturer Merck takes steps to move manufacturing into the U.S., particularly in the form of a $1 billion state-of-the-art ...

Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.

Merck (NYSE:MRK) is restructuring its pharmaceutical business into two divisions, Oncology and Specialty/Pharma & Infectious Diseases, with new executive leadership. The move is described as a ...

At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.

Dec 17 (Reuters) - The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with multibillion-dollar potential, according to internal documents seen by ...

By Ludwig Burger and Patricia Weiss FRANKFURT, March 5 (Reuters) - Germany's Merck KGaA projected 2026 adjusted operating profit to slip by as much as 9.8%, hurt by negative currency effects and the ...